Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Long-Term Deferred Tax (2013 - 2016)

Eledon Pharmaceuticals posted quarterly Long-Term Deferred Tax of $65.6 million for Q4 2016, up 28.64% year-on-year from $51.0 million in Q1 2016, and up 28.64% on a QoQ basis from $51.0 million in Q4 2015.

Eledon Pharmaceuticals (ELDN) has 4 years of Long-Term Deferred Tax data on file, last reported at $65.6 million in Q4 2016.

  • For the quarter ending Q4 2016, Long-Term Deferred Tax rose 28.64% year-over-year to $65.6 million; the trailing twelve-month figure through Dec 2016 stood at $65.6 million (up 28.64% YoY), and the FY2016 full-year result was $65.6 million, up 28.64% from the prior year.
  • Long-Term Deferred Tax for Q4 2016 stood at $65.6 million, up from $51.0 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $65.6 million in Q4 2016 and bottomed at $24.4 million in Q4 2013.
  • The 4-year median for Long-Term Deferred Tax is $42.2 million (2014), against an average of $43.6 million.
  • The widest annual swing landed in 2015, when Long-Term Deferred Tax surged 53.37%; it then grew 28.64% in 2016.
  • A 4-year view of Long-Term Deferred Tax shows it stood at $24.4 million in 2013, then surged by 36.35% to $33.3 million in 2014, then soared by 53.37% to $51.0 million in 2015, then gained by 28.64% to $65.6 million in 2016.
  • The last three Long-Term Deferred Tax figures came in at $65.6 million (Q4 2016), $51.0 million (Q4 2015), and $33.3 million (Q4 2014), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Eledon Pharmaceuticals 419.90 Mn 203.87 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2016 65.64 Mn
Dec 31, 2015 51.03 Mn
Dec 31, 2014 33.27 Mn
Dec 31, 2013 24.40 Mn